Article Text

Download PDFPDF
CASE REPORT
Use of cinacalcet in lithium-induced hyperparathyroidism
  1. Michael Dixon1,
  2. Vikram Luthra2,
  3. Christopher Todd3
  1. 1Pharmacy, Leeds and York Partnership NHS Foundation Trust, Leeds, UK
  2. 2Medical Psychotherapy Service, Leeds and York Partnership NHS Foundation Trust, Leeds, UK
  3. 3Department of Pharmacy, Bradford District Care NHS Foundation Trust, Bradford, UK
  1. Correspondence to Michael Dixon, michael.dixon1{at}nhs.net

Summary

The case of a 61-year-old female patient with a long-standing history of bipolar affective disorder treated medically with lithium therapy for the past two decades. In late 2012, the patient was diagnosed with hyperparathyroidism secondary to lithium therapy. The patient underwent parathyroidectomy in August 2013. During surgery, only two glands were conclusively located and removed. This resulted in a reduction in the patient’s plasma total calcium levels and parathyroid hormone. The psychiatric management of the bipolar affective disorder was reviewed, and lithium discontinued as a result of the findings. Over the following year, a variety of different mood stabilisers were trialled, however none were found to successfully maintain the patient’s mental health. In August 2014, the patient was admitted with a severe depressive relapse of her bipolar affective disorder. Her admission tests showed hypercalcaemia, which may also have contributed to her mood symptoms and mental state deterioration. The patient was reviewed by the endocrinology team and subsequently commenced on cinacalcet treatment (30 mg twice a day). Over the following months, the patient’s plasma total calcium levels returned to within normal range. The patient’s depressive symptomatology gradually improved with a combination of physical and pharmacological treatments.

  • psychiatry (drugs and medicines)
  • contraindications and precautions

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors All the authors contributed to the care of the patient and the writing of the article. MD, VL, CT: planning, writing and reviewing drafts of the article. MD: obtaining the consent from the patient. Submission of the final version of the article for publication.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.